1. Home
  2. BDX

as of 11-12-2026 3:50pm EST

$215.59
+$2.46
+1.15%
Stocks Health Care Medical/Dental Instruments Nasdaq

Following the separation of the life science segment, Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.

Founded: 1897 Country:
United States
United States
Employees: N/A City: FRANKLIN LAKES
Market Cap: 54.6B IPO Year: 1999
Target Price: $226.14 AVG Volume (30 days): 1.8M
Analyst Decision: Buy Number of Analysts: 16
Dividend Yield:
1.98%
Dividend Payout Frequency: monthly
EPS: 1.59 EPS Growth: -0.68
52 Week Low/High: $140.11 - $216.74 Next Earning Date: 11-05-2026
Revenue: $21,840,000,000 Revenue Growth: 8.24%
Revenue Growth (this year): 1.74% Revenue Growth (next year): 4.24%
P/E Ratio: 134.67 Index:
Free Cash Flow: 3.9B FCF Growth: +3.67%

Stock Insider Trading Activity of Becton Dickinson and Company (BDX)

Polen Thomas E Jr

Chairman, CEO and President

Sell
BDX Nov 5, 2026

Avg Cost/Share

$210.00

Shares

2,993

Total Value

$628,530.00

Owned After

110,163

SEC Form 4

Feld Michael

EVP, Chief Revenue Officer

Sell
BDX Oct 26, 2026

Avg Cost/Share

$198.13

Shares

76

Total Value

$15,057.88

Owned After

19,568

SEC Form 4

Feld Michael

EVP, Chief Revenue Officer

Sell
BDX Aug 26, 2026

Avg Cost/Share

$188.49

Shares

165

Total Value

$31,100.85

Owned After

19,568

SEC Form 4

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K SELL

Nov 5, 2026 · 100% conf.

AI Prediction SELL

1D

-2.77%

$203.40

Act: -0.48%

5D

-3.52%

$201.83

20D

-2.98%

$202.96

Price: $209.19 Prob +5D: 0% AUC: 1.000
0001628280-26-070511

EX-99.01

2 ex9919302026.htm

EX-99.01

Document

*Exhibit 99.1

1 Becton Drive

Franklin Lakes, NJ 07417

www.bd.com

Contacts:

Investors: Shawn Bevec, SVP, Investor Relations - investor.relations@bd.com

Media: Matt Marcus, VP, Public Relations - matt.marcus@bd.com

BD Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results

•Q4 revenue of $5.3 billion increased 5.4% as reported, 5.6% FXN

•Q4 GAAP and adjusted diluted EPS of $2.52 and $4.15, respectively

•FY26 revenue of $19.5 billion increased 4.9% as reported, 3.9% FXN

•FY26 GAAP and adjusted diluted EPS of $5.06 and $12.70, respectively

•FY26 cash from continuing operations increased 30.0% to $3.6 billion and free cash flow increased 42.5% to $2.9 billion

•Company issues FY27 guidance

FRANKLIN LAKES, NJ (November 5, 2026) - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 fourth quarter and full year, which ended September 30, 2026.

"We delivered a strong fourth quarter, with 5.6% revenue growth and broad-based performance led by our key growth platforms," said Tom Polen, chairman, CEO and president of BD. "Fiscal 2026 was a defining year as we completed BD's transformation to a more focused MedTech company with separation of our Life Sciences business. We strengthened our core growth and expanded BD Excellence to elevate our commercial capabilities, accelerate innovation and drive greater productivity. We enter fiscal 2027 from a position of strength, with a portfolio built for durable performance and confidence in the long-term growth, earnings and cash-flow potential of New BD."

Recent Business Highlights

•BD announced a landmark partnership with the U.S. Government to expand domestic manufacturing and strengthen the resilience of supply chains for America's essential medical consumables.

•Through this partnership, BD intends to invest $19 billion in the U.S. over several years, including capital, operational and supply chain investments, with $3 billion directed toward manufacturing expansion.

•The agreement also provides relief from future tariffs imposed under Section 232 on covered BD products and inputs, subject to the final scope and implementation of any future Section 232 actions and BD's achievement of agreed milestones.

•Connected Care:

•Announced that Fairview Health Services is the first health system in the U.S. to deploy the BD® Vmax™ 160 Pharmacy Automation Robot, a next-generation solution that expands beyond traditional dispensing to manage specialty therapies and refrigerated medications in high-volume, centralized outpatient pharmacy operations.

Page 1

•Interventional:

•Strengthened its leadership in peripheral vascular innovation:

•Announced the BD® Liverty™ TIPS Stent Graft U.S. launch, advancing portal hypertension care with a next‑generation interventional solution for patients with advanced liver disease, building on established clinical and physician experience in Europe and supported by six-month interim results from the ARCH clinical study.

•Announced positive nine-month results from the iliac cohort of the AGILITY clinical trial of the BD® Revello™ Vascular Covered Stent, with data demonstrating high vessel patency, low reintervention rates and meaningful improvements in mobility and symptoms, providing evidence supporting the treatment of complex iliac artery disease.

•Announced significant milestones in its advanced tissue regeneration strategy and expansion efforts:

•Surpassed the first enrollment milestone in the STANCE clinical trial evaluating BD® GalaFLEX LITE™ Scaffold in breast revision surgery for capsular contracture and malposition, the most frequent complication of implant-based breast surgery.

•Completed enrollment in the landmark PREVENT clinical trial, the first large-scale randomized study evaluating BD® Phasix™ Mesh for incisional hernia prevention, a significant unmet need following abdominal surgery.

The company will hold its 2026 Investor Day on December 10th at the New York Stock Exchange. Additional information will be forthcoming.

Basis of Presentation— Continuing Operations

On February 9, 2026, the company completed the spin-off of BD's former Biosciences and Diagnostic Solutions business and the combination of the business with Waters Corporation ("Waters"). The historical results of the former Biosciences and Diagnostic Solutions business, which was previously the Life Sciences segment, are reflected as discontinued operations for all periods presented. Financial information presented in this release reflects BD's results on a continuing operations basis. Prior periods have been recast to conform to this presentation.

Fourth Quarter Fiscal 2026 Operating Results

(Millions of dollars, except per share amounts)Three Months Ended September 30,Reported Change Foreign Currency Neutral Change1

20262025

Revenues$5,274 $5,005 5.4 %5.6 %

Reported Diluted Earnings per Share$2.52 $

2026
Q2

Q2 2026 Earnings

8-K BUY

Aug 6, 2026 · 100% conf.

AI Prediction BUY

1D

+1.08%

$178.98

Act: -0.12%

5D

+3.09%

$182.54

20D

+2.57%

$181.62

Price: $177.07 Prob +5D: 100% AUC: 1.000
0001628280-26-053790

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.c706d217.1786061739.e0aafa20

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

2026
Q1

Q1 2026 Earnings

8-K SELL

May 7, 2026 · 100% conf.

AI Prediction SELL

1D

-2.79%

$148.98

Act: -2.52%

5D

-3.32%

$148.17

Act: -5.74%

20D

-3.19%

$148.38

Act: -1.37%

Price: $153.26 Prob +5D: 0% AUC: 1.000
0001628280-26-031638

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.c706d217.1784665128.25cfcf0e

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

Share on Social Networks: